99.97%
Total purityReport 2608131067 · Supplier batch B07E4-C · Freedom Diagnostics Testing · Completed Aug 20, 2026
- Report
- 2608131067
- Report date
- Aug 20, 2026
- Labelled
- 10 mg Vial
- Measured
- 10.46 mg

Size10 mg Vial
Quantity pricing
Buying several compounds?
These are the reported results for this exact presentation. A published report does not establish which physical lot is currently in stock.
Browse the COA library Print specification sheet99.97%
Total purityReport 2608131067 · Supplier batch B07E4-C · Freedom Diagnostics Testing · Completed Aug 20, 2026
| Analysis | Result | Status |
|---|---|---|
| Identity | PT-141 | Confirmed |
| Purity | 99.97% | Reported |
| Net content | 10.46 mg | Reported |
| Appearance | White Lyophilized Powder | Reported |
Only the assays this certificate reports are listed here. A reported value does not imply a passing specification.
PT-141 peptide reference material for in-vitro laboratory research and analytical method development. Research use only. Not for human or veterinary use; no therapeutic, preventive, or diagnostic claims are made or implied.
Explore published literature Search PubMed for PT-141Refer to the product label and lot-specific documentation for storage and handling instructions.
PT-141 supplied in the selected 10 mg Vial presentation. Other supplies are listed separately unless explicitly included in an offer.
Open the published report for this presentation. Check its product code and any printed lot against your vial.
PT-141 is a synthetic alpha-melanocyte-stimulating hormone analogue, heptapeptide of 7 amino acids. Based on alpha-melanocyte-stimulating hormone (alpha-MSH).
Reported to activate central nervous system melanocortin receptors MC3R and MC4R. Its reported site of action is central, not vascular — which is what distinguishes it from PDE5 inhibitors. We make no claim as to mechanism or effect.
An FDA-approved product containing this moiety exists, approved 2019 for one indication in one population under its own labelling. A research-use reference material is not that product.
Originally developed by Palatin Technologies, evaluated in Phase 3 trials for hypoactive sexual desire disorder in premenopausal women, and approved by FDA in 2019. First described by Palatin Technologies.
Studied in melanocortin receptor signalling. We supply it as a reference material for in-vitro laboratory research and analytical method development only.
Approved for one indication in one population on Phase 3 evidence. Off-label use in men is reported but is not what the approval covers.
Explore the published literature on PT-141. Start with the original papers, study methods and reported limitations.
Publications describe research on the molecule. They do not verify the identity, purity or performance of a Vectra product lot. Consult available product documentation for reported testing results.
Check the published report's product code and any printed lot against your product.
These products are intended for laboratory research. Not for human or veterinary use.



Size10 mg Vial
Quantity pricing
Buying several compounds?
These are the reported results for this exact presentation. A published report does not establish which physical lot is currently in stock.
Browse the COA library Print specification sheet99.97%
Total purityReport 2608131067 · Supplier batch B07E4-C · Freedom Diagnostics Testing · Completed Aug 20, 2026
| Analysis | Result | Status |
|---|---|---|
| Identity | PT-141 | Confirmed |
| Purity | 99.97% | Reported |
| Net content | 10.46 mg | Reported |
| Appearance | White Lyophilized Powder | Reported |
Only the assays this certificate reports are listed here. A reported value does not imply a passing specification.
PT-141 peptide reference material for in-vitro laboratory research and analytical method development. Research use only. Not for human or veterinary use; no therapeutic, preventive, or diagnostic claims are made or implied.
Explore published literature Search PubMed for PT-141Refer to the product label and lot-specific documentation for storage and handling instructions.
PT-141 supplied in the selected 10 mg Vial presentation. Other supplies are listed separately unless explicitly included in an offer.
Open the published report for this presentation. Check its product code and any printed lot against your vial.
PT-141 is a synthetic alpha-melanocyte-stimulating hormone analogue, heptapeptide of 7 amino acids. Based on alpha-melanocyte-stimulating hormone (alpha-MSH).
Reported to activate central nervous system melanocortin receptors MC3R and MC4R. Its reported site of action is central, not vascular — which is what distinguishes it from PDE5 inhibitors. We make no claim as to mechanism or effect.
An FDA-approved product containing this moiety exists, approved 2019 for one indication in one population under its own labelling. A research-use reference material is not that product.
Originally developed by Palatin Technologies, evaluated in Phase 3 trials for hypoactive sexual desire disorder in premenopausal women, and approved by FDA in 2019. First described by Palatin Technologies.
Studied in melanocortin receptor signalling. We supply it as a reference material for in-vitro laboratory research and analytical method development only.
Approved for one indication in one population on Phase 3 evidence. Off-label use in men is reported but is not what the approval covers.
Explore the published literature on PT-141. Start with the original papers, study methods and reported limitations.
Publications describe research on the molecule. They do not verify the identity, purity or performance of a Vectra product lot. Consult available product documentation for reported testing results.
Check the published report's product code and any printed lot against your product.
These products are intended for laboratory research. Not for human or veterinary use.


Our sources carry no CAS number, formula, molecular weight, sequence, safety data, or storage data for PT-141.
An approved product containing this moiety exists (2019). This material is supplied for in-vitro research use only. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
Our sources carry no CAS number, formula, molecular weight, sequence, safety data, or storage data for PT-141.
An approved product containing this moiety exists (2019). This material is supplied for in-vitro research use only. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.